Lupin sales jump 33% as pharma majors pivot to India, emerging markets
Lupin posted a 33.3% year-on-year sales jump to ₹8,217 crore in Q1 FY27, with EBITDA rising 42.8% to ₹2,580 crore and profit after tax up 16% to ₹1,417 crore. The company attributed…
Ashin Xavier: interesting
IO Repro: Repro test v4 after fix 2 Oct. Safe to trash.
IO Repro: Repro test v3 after fix 2 Oct. Safe to trash.
IO Repro: Repro test after fix 2 Oct. Safe to trash.